Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1989-2-15
pubmed:abstractText
The antihypertensive effect of nicardipine was evaluated in 89 ambulatory elderly patients with hypertension through a multicenter trial enrolling patients over the age of 65 years. After a baseline period during which they received placebo, subjects were randomized by an unbalanced assignment to a double-blind comparison of nicardipine (n = 57) and placebo (n = 32). The initial dose of nicardipine was 20 mg every 8 hours, which was then increased to 30 mg if needed. Blood pressure and heart rate were measured 1 and 8 hours after doses at each visit with subjects in both the supine and standing positions. Seventy-six per cent of patients who received nicardipine and 55% who received placebo responded (p less than 0.05). During standing, blood pressure did not decrease significantly from supine levels in either group, but a small, transient increase in heart rate occurred with nicardipine. Adverse reactions (apart from failure to respond) occurred in 8% of those who received nicardipine and 3% who received placebo. Three patients were withdrawn: two for symptoms, nausea, or flushing and one for transient and asymptomatic abnormalities on ECG. Nicardipine is effective and safe as monotherapy in elderly patients with hypertension, causing greater reduction in systolic than in diastolic pressure, but without orthostatic hypotension.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0002-8703
pubmed:author
pubmed:issnType
Print
pubmed:volume
117
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
250-5
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Nicardipine monotherapy in ambulatory elderly patients with hypertension.
pubmed:affiliation
Hypertension Division, Mount Sinai Hospital, New York, NY 10029.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study